-
FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC
19 Apr 2024 21:32 GMT
… Patients With ALK Positive Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: … lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) as detected by an … Patients With ALK Positive Non-Small Cell Lung Cancer.ClinicalTrials.gov identifier: NCT03456076 …
-
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
18 Apr 2024 21:57 GMT
… lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA … patients with ALK-positive NSCLC who had complete tumor resection … ≥ 4 cm) to IIIA NSCLC (by AJCC 7th edition) with … patients with stage II-IIIA NSCLC, median DFS was not …
-
Moffitt Researchers Discover New Therapeutic Target for Non-Small Cell Lung Cancer
18 Apr 2024 15:02 GMT
Newswise — TAMPA, Fla. — Non-small cell lung cancer accounts for nearly 85% of …
-
Roche wins second FDA label expansion for Alecensa in NSCLC
19 Apr 2024 17:03 GMT
… lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Alecensa was approved as … for metastatic ALK-positive NSCLC by the US FDA … therapy for ALK-positive NSCLC with multiple global health … death by 76% in NSCLC patients with completely resected …
-
AstraZeneca’s Tagrisso maintains momentum in NSCLC with FLAURA2 results
19 Apr 2024 15:46 GMT
… -related deaths per year.
Non-small cell lung cancer (NSCLC) constitutes around 85% of … choice for patients with NSCLC.
With advances in biomarker … advanced or metastatic EGFRm NSCLC, specifically EGFR exon 19 … (NCCN) for treating NSCLC with EGFR exon 19 …
-
Genentech's Alecensa Approved in Early-Stage NSCLC
19 Apr 2024 14:44 GMT
… anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA … resected tumor in ALK-positive NSCLC. In an exploratory analysis, an … treatment for ALK-positive metastatic NSCLC. It has demonstrated significant efficacy …
-
Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC
19 Apr 2024 11:39 GMT
… for patients with ALK-positive non-small cell lung cancer (NSCLC), as detected by an FDA … of cancer death globally and NSCLC represents up to 85% of … treatment for ALK-positive, metastatic NSCLC.
Commenting on the latest authorisation …
-
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
17 Apr 2024 12:00 GMT
… line treatment of metastatic non-small cell lung cancer (1L NSCLC).
Immutep SVP, Regulatory … therapy in first line non-small cell lung cancer.” The AEMPS is supportive … of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous …
-
FDA clears Roche’s Alecensa for adjuvant use in NSCLC
19 Apr 2024 09:46 GMT
… in early-stage, ALK-positive non-small cell lung cancer (NSCLC).
The approval is significant … death in early-stage NSCLC when compared to platinum- … those with other types of NSCLC,” he said. “Now, … with advanced, metastatic ALK-positive NSCLC, and is a big …
-
FDA Approves Alecensa for ALK-Positive NSCLC
18 Apr 2024 22:33 GMT
… of patients with ALK-positive non-small cell lung cancer (NSCLC) that is 4 cm or … for patients with early-stage NSCLC that has undergone surgical … those with other types of NSCLC. Now, with this significant … 1B to 3A ALK-positive NSCLC.
In patients with stage …